Yahoo Finance • 12 days ago
Baird Asset Management, which controls Chautauqua Capital Management, a boutique investment firm, released its second quarter 2025 investor letter for the "Baird Chautauqua International and Global Growth Fund". A copy of the letter can be... Full story
Yahoo Finance • 15 days ago
[Many different pills on pink background. Prescription pills and vitamins. Flat lay and space for text.] Baurzhan Ibrashev European and Asian pharmaceutical stocks fell Friday after President Donald Trump unveiled sweeping new tariffs, in... Full story
Yahoo Finance • last month
In recent trading, shares of BeOne Medicines Ltd (Symbol: ONC) have crossed above the average analyst 12-month target price of $345.89, changing hands for $346.45/share. When a stock reaches the target an analyst has set, the analyst logi... Full story
Yahoo Finance • last month
[Lymphoma blood test] BeOne Medicines (NASDAQ:ONC [https://seekingalpha.com/symbol/ONC]) announced Friday that sonrotoclax, its experimental therapy targeting a hematological cancer called mantle cell lymphoma, succeeded as a late-line op... Full story
Yahoo Finance • 2 months ago
BeOne Medicines (NASDAQ:ONC [https://seekingalpha.com/symbol/ONC]) is selling its royalty rights on the worldwide sales, excluding China, of Amgen’s (NASDAQ:AMGN [https://seekingalpha.com/symbol/AMGN]) cancer drug Imdelltra (tarlatamab-dll... Full story
Yahoo Finance • 2 months ago
Biotech stocks are performing well in the stock market in August and a few in the IBD 50 have formed bases with clear buy points. Continue Reading View Comments... Full story
Yahoo Finance • 2 months ago
SAN DIEGO - Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), whose stock has delivered an impressive 56% return year-to-date according to InvestingPro data, reported Monday that shareholders elected all eight director nominees at its Annua... Full story
Yahoo Finance • 2 months ago
Exploring the Latest 13F Filing and Investment Adjustments Baillie Gifford (Trades, Portfolio) recently submitted the 13F filing for the second quarter of 2025, providing insights into its investment moves during this period. Established... Full story
Yahoo Finance • 2 months ago
Earnings Call Insights: BeOne Medicines Ltd. (ONC) Q2 2025 MANAGEMENT VIEW * John V. Oyler, CEO, reported "Our revenue reached $1.3 billion, which represents 42% year-on-year growth. GAAP earnings per ADS grew $2 from Q2 of last year,... Full story
Yahoo Finance • 2 months ago
Onc stock reached a significant milestone, hitting a 52-week high of 309.25 USD. The $36.11 billion market cap company’s achievement reflects a robust performance over the past year, during which BeOne Medicines AG DRC, the company behind... Full story
Yahoo Finance • 2 months ago
Over the last 7 days, the United States market has remained flat, yet it has experienced a notable increase of 17% over the past year with earnings forecasted to grow by 15% annually. In this environment, identifying stocks that are tradin... Full story
Yahoo Finance • 2 months ago
[The European Medicines Agency (<a href='https://seekingalpha.com/symbol/EMA' title='Emera Incorporated'>EMA</a>). The stamp and an imprint] Waldemarus * The European Medicines Agency's Committee for Medicinal Products for Human Use ("C... Full story
Yahoo Finance • 3 months ago
SAN DIEGO/CALGARY - Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), a $34.64 billion market cap company, has regained compliance with Nasdaq’s minimum bid price requirement, according to a formal notice received Tuesday from the exchange’... Full story
Yahoo Finance • 3 months ago
When InvestingPro’s Fair Value model flagged MAIA Biotechnology (NYSE:MAIA) as overvalued in April 2024, the clinical-stage biotechnology company was trading at $2.90. Today, the stock trades at $1.69, validating the model’s assessment wit... Full story
Yahoo Finance • 3 months ago
This cancer treatment stock is nearing a buy point of a base. Shares have already gained 50% so far this year. Continue Reading View Comments... Full story
Yahoo Finance • 3 months ago
Tuesday’s market has witnessed notable fluctuations across a spectrum of stocks, with companies such as Alibaba-exch (BABA) and Adv Micro Device (NASDAQ:AMD) experiencing significant gains, while others like Wells Fargo (WFC) have faced... Full story
Yahoo Finance • 3 months ago
(Reuters) -AstraZeneca is in talks with Summit Therapeutics (NASDAQ:SMMT) to license an experimental lung-cancer drug under a deal worth as much as $15 billion, Bloomberg News reported on Thursday, citing people familiar with the matter.... Full story
Yahoo Finance • 3 months ago
Morgan Stanley raised the firm’s price target on BeOne Medicines (ONC) to $330 from $313 and keeps an Overweight rating on the shares following the R&D day that highlighted the company’s pipeline programs. Management is targeting a 2026 ap... Full story
Yahoo Finance • 3 months ago
Friday’s trading session is showcasing significant movements among several stocks, particularly within the mega-cap and large-cap categories. Stocks like Palantir Technologies Inc (NASDAQ:PLTR) and General Electric (NYSE:GE) are experi... Full story
Yahoo Finance • 4 months ago
BRUKINSA, sonrotoclax, and BTK CDAC data, including combinations, are designed to comprehensively address unmet needs across CLL patient populations Promising new data from pipeline assets in breast, lung, and GI cancer franchises, includ... Full story